{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:09Z","timestamp":1790487069756,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T00:00:00Z","timestamp":1499472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12185-017-2295-0","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T06:23:26Z","timestamp":1499495006000},"page":"355-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Treatment-free remission in patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"108","author":[{"given":"Delphine","family":"Rea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,8]]},"reference":[{"issue":"23","key":"2295_CR1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, IRIS Investigators, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"2295_CR2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, IRIS Investigators, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"19","key":"2295_CR3","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1158\/0008-5472.CAN-12-1276","volume":"72","author":"O Hantschel","year":"2012","unstructured":"Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012;72(19):4890\u20135.","journal-title":"Cancer Res"},{"issue":"21","key":"2295_CR4","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2014-10-567784","volume":"125","author":"AJ Barrett","year":"2015","unstructured":"Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood. 2015;125(21):3230\u20135.","journal-title":"Blood"},{"issue":"3","key":"2295_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14(3):141\u201354.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2295_CR6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553\u201361.","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"2295_CR7","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2295_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319\u201325.","journal-title":"Blood"},{"issue":"1","key":"2295_CR9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396\u2013409.","journal-title":"J Clin Invest."},{"issue":"20","key":"2295_CR10","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565\u201372.","journal-title":"Blood"},{"issue":"6","key":"2295_CR11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310.","journal-title":"Blood"},{"issue":"6","key":"2295_CR12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"1","key":"2295_CR13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood. 2007;109(1):58\u201360.","journal-title":"Blood"},{"issue":"11","key":"2295_CR14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2295_CR15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322.","journal-title":"Blood"},{"issue":"3","key":"2295_CR16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298\u2013305.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2295_CR17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NC Cross","year":"2015","unstructured":"Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999\u20131003.","journal-title":"Leukemia"},{"issue":"5","key":"2295_CR18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424\u201330.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2295_CR19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","volume":"88","author":"SE Lee","year":"2013","unstructured":"Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013;88(6):449\u201354.","journal-title":"Am J Hematol"},{"issue":"6","key":"2295_CR20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717\u201323.","journal-title":"Haematologica"},{"key":"2295_CR21","doi-asserted-by":"crossref","unstructured":"Mahon FX, Richter J, Guilhot J, Hjorth-Hansen H, Almeida A, Janssen JWM, et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood. 2016;128(22): abstract 787.","DOI":"10.1007\/978-3-319-33198-0_13"},{"issue":"10","key":"2295_CR22","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540\u20136.","journal-title":"Blood"},{"issue":"19","key":"2295_CR23","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, R\u00e9a D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204\u201312.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2295_CR24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","volume":"124","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124(5):729\u201336.","journal-title":"Blood"},{"issue":"20","key":"2295_CR25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2295_CR26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"12","key":"2295_CR27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, DADI Trial Group, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1\u00a0year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):528\u201335.","journal-title":"Lancet Haematol"},{"key":"2295_CR28","doi-asserted-by":"crossref","unstructured":"Shah NP, Paquette R, M\u00fcller MC, Saussele S, Garc\u00eca-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, et al. Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib\u2014the Dasfree Study. Blood. 2016;128(22): abstract 1895.","DOI":"10.1182\/blood.V128.22.1895.1895"},{"issue":"7","key":"2295_CR29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846\u201354.","journal-title":"Blood"},{"key":"2295_CR30","doi-asserted-by":"crossref","unstructured":"Hughes TP, Boquimpani CM, Takahashi N, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission in patients with chronic myeloid leukemia in chronic phase according to reasons for switching from imatinib to nilotinib: subgroup analysis from ENESTop. Blood. 2016;128(22): abstract 792.","DOI":"10.1182\/blood.V128.22.792.792"},{"key":"2295_CR31","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: results from the ENESTFreedom study. J Clin Oncol. 2016; 34(suppl; abstr 7001).","DOI":"10.1200\/JCO.2016.34.15_suppl.7001"},{"key":"2295_CR32","doi-asserted-by":"crossref","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese trial (D-STOP trial). Blood. 2016;128(22): abstract 791.","DOI":"10.1182\/blood.V128.22.791.791"},{"key":"2295_CR33","doi-asserted-by":"crossref","unstructured":"Kadowaki N, Kawaguchi T, Kurod J, Nakamae H, Matsumura I, Miyamoto T, et al. Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: a multicenter phase 2 stop nilotinib (nilst) trial. Blood. 2016; 128(22): abstract 790.","DOI":"10.1182\/blood.V128.22.790.790"},{"key":"2295_CR34","doi-asserted-by":"crossref","unstructured":"Takahashi N, Nakaseko C, Nishiwaki K, Wakita H. Two-year consolidation by nilotinib is associated with successful treatment free remission in chronic myeloid leukemia with MR4.5: subgroup analysis from STAT2 trial in Japan. Blood. 2016;128(22): abstract 1889.","DOI":"10.1182\/blood.V128.22.1889.1889"},{"key":"2295_CR35","doi-asserted-by":"crossref","unstructured":"Rea D, Rosti G, Cross NCP, Hellmann A, Niederwieser D, Pungolino E, et al. ENESTPath: A phase 3 study to assess the effect of nilotinib treatment duration on treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with imatinib: 24-month analysis of the first 300 patients in the induction\/consolidation phase. Blood. 2016;128(22): abstract 3094.","DOI":"10.1182\/blood.V128.22.3094.3094"},{"issue":"6","key":"2295_CR36","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/bjc.2013.318","volume":"109","author":"WT Parker","year":"2013","unstructured":"Parker WT, Yeoman AL, Jamison BA, Yeung DT, Scott HS, Hughes TP, et al. BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer. 2013;109(6):1593\u20138.","journal-title":"Br J Cancer"},{"issue":"2","key":"2295_CR37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","volume":"107","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S, Rios MB, Abruzzo L, Verstovsek S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006;107(2):480\u20132.","journal-title":"Blood"},{"issue":"1","key":"2295_CR38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/10428194.2015.1043548","volume":"57","author":"R Latagliata","year":"2016","unstructured":"Latagliata R, Romano A, Mancini M, Breccia M, Carmosino I, Vozella F, et al. Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. Leuk Lymphoma. 2016;57(1):99\u2013102.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2295_CR39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.bmt.1701729","volume":"23","author":"AS Yong","year":"1999","unstructured":"Yong AS, Goldman JM. Relapse of chronic myeloid leukaemia 14\u00a0years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23(8):827\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2295_CR40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","volume":"57","author":"JS Park","year":"2016","unstructured":"Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, et al. Change of health-related profiles after imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma. 2016;57(2):341\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2295_CR41","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, S\u00f6derlund S, L\u00fcbking A, Dreimane A, Lotfi K, Markev\u00e4rn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32(25):2821\u20133.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2295_CR42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood-2016-12-757302","volume":"129","author":"P Laneuville","year":"2017","unstructured":"Laneuville P. Stopping second-generation TKIs in CML. Blood. 2017;129(7):805\u20136.","journal-title":"Blood"},{"issue":"10","key":"2295_CR43","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910\u20134.","journal-title":"Am J Hematol"},{"issue":"3","key":"2295_CR44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","volume":"126","author":"B Zhang","year":"2016","unstructured":"Zhang B, Li L, Ho Y, Li M, Marcucci G, Tong W, et al. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. J Clin Invest. 2016;126(3):975\u201391.","journal-title":"J Clin Invest"},{"issue":"1","key":"2295_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17\u201323.","journal-title":"Blood"},{"issue":"8","key":"2295_CR46","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371.","journal-title":"Leukemia"},{"issue":"8","key":"2295_CR47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","volume":"9","author":"E Abruzzese","year":"2016","unstructured":"Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9(8):781\u201391.","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2295_CR48","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97(6):903\u20136.","journal-title":"Haematologica"},{"issue":"12","key":"2295_CR49","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3109\/10428194.2013.831092","volume":"55","author":"O Benjamini","year":"2014","unstructured":"Benjamini O, Kantarjian H, Rios MB, Jabbour E, O\u2019Brien S, Jain P, et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014;55(12):2879\u201386.","journal-title":"Leuk Lymphoma"},{"key":"2295_CR50","unstructured":"Rege-Cambrin G, Fava C, Dogliotti I, Berchialla P, Gottardi E, Cerrano M, et al. Imatinib discontinuation in chronic myeloid leukemia: a retrospective analysis on patients in clinical practice. Haematologica 2015;100(Supplement 1): abstract: P603."},{"key":"2295_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30608","author":"JH Kong","year":"2017","unstructured":"Kong JH, Winton EF, Heffner LT, Chen Z, Langston AA, Hill B, et al. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? Cancer. 2017;. doi: 10.1002\/cncr.30608 .","journal-title":"Cancer"},{"issue":"4","key":"2295_CR52","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13983","volume":"176","author":"D Ferrero","year":"2017","unstructured":"Ferrero D, Cerrano M, Cris\u00e0 E, Aguzzi C, Giai V, Boccadoro M. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience. Br J Haematol. 2017;176(4):669\u201371.","journal-title":"Br J Haematol"},{"issue":"6","key":"2295_CR53","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","volume":"15","author":"T Sato","year":"2009","unstructured":"Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med. 2009;15(6):696\u2013700.","journal-title":"Nat Med"},{"issue":"7240","key":"2295_CR54","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MA Essers","year":"2009","unstructured":"Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904\u20138.","journal-title":"Nature"},{"issue":"26","key":"2295_CR55","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, SPIRIT Investigators, France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (Fi-LMC), et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511\u201321.","journal-title":"N Engl J Med"},{"issue":"9","key":"2295_CR56","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2012-02-408229","volume":"120","author":"L Legros","year":"2012","unstructured":"Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, et al. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood. 2012;120(9):1959\u201360.","journal-title":"Blood"},{"issue":"12","key":"2295_CR57","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595\u2013606.","journal-title":"Blood"},{"key":"2295_CR58","unstructured":"Rea D, Dulphy N, Henry G, Guilhot J, Guilhot F, Nicolini FE, et al. Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2\u00a0years: preliminary results from Immunostim, on behalf of STIM Investigators (abstract). Blood. 2013;122(21): abstract 856."},{"key":"2295_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.360","author":"M Ilander","year":"2016","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H, Guilhot J, Br\u00fcck O, L\u00e4hteenm\u00e4ki H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2016;. doi: 10.1038\/leu.2016.360 .","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2295-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2295-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T20:46:56Z","timestamp":1602449216000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2295-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,8]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2295-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,8]]}}}